我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
61
9 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
5
8.2%
已完成
41
67.2%
尚未招募
4
6.6%
招募中
3
4.9%
Unknown
暂无批准数据
- Novartis AG has executed a definitive agreement to sell its entire 70.68% controlling stake in Novartis India Limited to a consortium of three investment firms for approximately $345 million. - The transaction automatically triggers a mandatory open offer under SEBI regulations, requiring the acquiring consortium to offer purchase opportunities to all remaining public shareholders. - Novartis India's recent financial performance shows declining trends with Q3 revenue falling 8% year-over-year to ₹859 million and net profit dropping 37% to ₹161 million. - The strategic divestment allows Novartis AG to retain its R&D operations through Novartis Healthcare Private Limited while exiting commercial operations in India's competitive pharmaceutical market.
